Motif Bio plc – updated Shard Capital research note

18 January 2017

Shard Capital Research Note

Motif is a clinical stage development company focused on a best-in-class drug that is targeting bacteria that are resistant to most other commonly used antibiotics. The FDA has agreed a plan of two carefully constructed Phase III trials that will allow approval of iclaprim, opening it up to a $3.0bn market segment. Following a recent NASDAQ IPO and EU Placing, the company has sufficient capital to complete the first trial (REVIVE-1). Further funds will be required to complete the second trial later in 2017, and to conduct a Phase III trial in nosocomial pneumonia. Headline data from REVIVE-1 is due 2Q’17, with REVIVE-2 in 2H’17.

Please click here to view Shard Capital’s updated Research note.